JOMPAC
Journal of Medicine and Palliative Care

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

eISSN: 2717-7505
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
A noteworthy prognostic marker in extensive small cell lung cancer: lymphocyte/C-reactive protein ratio
Abstract
Aims: We aimed to investigate the pre-treatment prognostic significance of lymphocyte/C-Reactive protein ratio (LCR), one of the inflammatory factors, in patients with extensive-stage small cell lung cancer (SCLC).
Methods: Medical records of 514 patients who were diagnosed with extensive-stage SCLC between 2010 and 2020 were examined retrospectively. LCR was calculated using the blood test results prior to chemotherapy.
Results: The mean survival time for extensive-stage SCLC is 6 months (5.3-6.7). A statistically significant difference exists between limited and extensive stages in terms of median overall survival (OS) (p<0.001). The baseline LCR value of the patients was determined as 0.5 (0-311). LCR exerts a statistically significant effect on overall survival (0.025). Every 1 unit increase in LCR reduces death by 1.004 times.
Conclusion: Pre-treatment LCR value can be used as an independent prognostic parameter associated with mean survival in extensive SCLC.

Keywords : Small cell lung cancer, lymphocyte/CRP ratio, prognostic factor, survival

Download Article


1. Govindan R, Page N, Morgensztern D, et al. Changingepidemiology of small-cell lung cancer in the United States overthe last 30 years: analysis of the surveillance, epidemiologic, andend results database. J Clin Oncol. 2006;24(28):4539-4544.
2. Bernhardt EB, Jalal SI. Small cell lung cancer. Cancer Treat Res.2016;170:301-322.
3. Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N.Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987;39(2):146-149.
4. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers,Mechanisms, and Consequences. Immunity. 2019;51(1):27-41.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-relatedinflammation. Nature. 2008; 454(7203):436-444.
6. Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value ofsystemic immune-inflammation index in cancer: a meta-analysis.J Cancer. 2018;9:3295-3302.
7. Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammationresponse index (SIRI) for predicting the survival of patients withpancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158-2167.
8. Li S, Yang Z, Du H, Zhang W, Che G, Liu L. Novel systemicinflammation response index to predict prognosis afterthoracoscopic lung cancer surgery: a propensity score-matchingstudy. ANZ J Surg. 2019;89(11):E507-E513.
9. &Ouml;zt&uuml;rk Erg&uuml;r F, &Ouml;zt&uuml;rk A. A new prognostic marker in smallcell lung cancer: red cell distribution width ratio of hemoglobin.Anatolian Curr Med J. 2023; 5(2); 148-152.
10. Bozkaya Y, Kurt B, G&uuml;rler F. A prognostic parameter in advancednon-small cell lung cancer: the ratio of hemoglobin-to-red celldistribution width. Int J Clin Oncol. 2019;24:798-806.
11. He Y, Gong R, Peng KW, Liu LZ, Sun LY, Wang HY. Lymphocyte-to-C-reactive protein ratio is a potential new prognosticbiomarker for patients with lung cancer. Biomark Med.2020;14(9):717-726.
12. Yılmaz H, Yersal &Ouml;. Prognostic significance of novel inflammatorymarkers in extensive-stage small-cell lung cancer. J Can Res Ther.2022;18:691-696.
13. İriağa&ccedil; Y, &Ccedil;avdar E, Yolcu A. The prognostic importance oflymphocyte/monocyte ratio in diffuse stage small cell lungcancer. Ahi Evran Med J. 2022; 6 (1):71-76.
14. Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lungcancer - major changes in the American Joint Committee onCancer eighth edition cancer staging manual. CA Cancer J Clin.2017;67(2):138-155.
Article available in :
Volume 4, Issue 4, 2023
Page : 341-344
https://doi.org/10.47582/jompac.1332258
Article Information
Received : 24 Tem 2023
Accepted : 23 Ağu 2023
Published : 30 Ağu 2023
Corresponding Author :

Figen Öztürk Ergür: Department of Chest Disease, Ankara Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, University of Health Sciences, Ankara, Turkey

[email protected]
Citation : Öztürk Ergür F, Öztürk A, Uzel Şener M, Tilbe Saymaz Z, Mutlu N. A noteworthy prognostic marker in extensive small cell lung cancer: lymphocyte/C-reactive protein ratio. J Med Palliat Care. 2023;4(4):341-344.

Read: 136
Cited: 0
Download : 154
_Footer